Intellia Therapeutics (NASDAQ:NTLA) Rating Increased to Outperform at Citizens Jmp

Intellia Therapeutics (NASDAQ:NTLA) was upgraded by investment analysts at Citizens Jmp from a “market perform” rating to an “outperform” rating in a research note issued to investors on Monday,Finviz reports. The firm currently has a $33.00 price target on the stock. Citizens Jmp’s price target points to a potential upside of 65.33% from the company’s current price.

A number of other brokerages have also issued reports on NTLA. Wall Street Zen upgraded shares of Intellia Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, September 6th. Royal Bank Of Canada dropped their price objective on Intellia Therapeutics from $25.00 to $21.00 and set an “outperform” rating for the company in a research note on Friday, August 8th. Guggenheim restated a “buy” rating and set a $14.00 price objective on shares of Intellia Therapeutics in a research note on Wednesday, August 13th. JMP Securities raised shares of Intellia Therapeutics from a “market perform” rating to a “market outperform” rating and set a $33.00 price target on the stock in a report on Monday. Finally, HC Wainwright boosted their price objective on Intellia Therapeutics from $25.00 to $30.00 and gave the stock a “buy” rating in a research note on Friday, September 19th. Thirteen research analysts have rated the stock with a Buy rating, six have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, Intellia Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $27.95.

Intellia Therapeutics Price Performance

NASDAQ NTLA opened at $19.96 on Monday. The company’s 50 day simple moving average is $12.88 and its 200 day simple moving average is $10.33. The company has a market capitalization of $2.14 billion, a P/E ratio of -4.26 and a beta of 2.37. Intellia Therapeutics has a 12 month low of $5.90 and a 12 month high of $21.47.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.99) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.03) by $0.04. The business had revenue of $14.25 million for the quarter, compared to the consensus estimate of $12.26 million. Intellia Therapeutics had a negative return on equity of 57.48% and a negative net margin of 908.48%.The firm’s revenue was up 104.3% compared to the same quarter last year. During the same period last year, the business earned ($1.52) EPS. On average, analysts anticipate that Intellia Therapeutics will post -5.07 earnings per share for the current year.

Insider Activity at Intellia Therapeutics

In related news, Director William J. Chase purchased 100,000 shares of Intellia Therapeutics stock in a transaction dated Wednesday, August 20th. The stock was bought at an average cost of $10.03 per share, with a total value of $1,003,000.00. Following the purchase, the director owned 134,693 shares in the company, valued at approximately $1,350,970.79. The trade was a 288.24% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Edward J. Dulac III sold 7,462 shares of the company’s stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $14.02, for a total transaction of $104,617.24. Following the sale, the executive vice president directly owned 106,062 shares of the company’s stock, valued at $1,486,989.24. This represents a 6.57% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 9,364 shares of company stock valued at $137,674 over the last ninety days. Corporate insiders own 3.10% of the company’s stock.

Institutional Investors Weigh In On Intellia Therapeutics

Hedge funds have recently made changes to their positions in the stock. Cambridge Investment Research Advisors Inc. grew its holdings in shares of Intellia Therapeutics by 51.7% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 19,726 shares of the company’s stock worth $140,000 after purchasing an additional 6,722 shares during the last quarter. D.A. Davidson & CO. boosted its stake in Intellia Therapeutics by 76.2% during the 1st quarter. D.A. Davidson & CO. now owns 26,020 shares of the company’s stock worth $185,000 after acquiring an additional 11,250 shares during the last quarter. Voya Investment Management LLC increased its position in shares of Intellia Therapeutics by 621.5% in the 1st quarter. Voya Investment Management LLC now owns 208,009 shares of the company’s stock valued at $1,479,000 after buying an additional 179,180 shares in the last quarter. California State Teachers Retirement System increased its stake in Intellia Therapeutics by 4.1% during the 4th quarter. California State Teachers Retirement System now owns 90,638 shares of the company’s stock worth $1,057,000 after purchasing an additional 3,596 shares in the last quarter. Finally, Ballentine Partners LLC acquired a new stake in shares of Intellia Therapeutics during the second quarter worth $161,000. Institutional investors own 88.77% of the company’s stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.